Summit Place Financial Advisors LLC Acquires 75 Shares of Johnson & Johnson (NYSE:JNJ)

Summit Place Financial Advisors LLC grew its position in Johnson & Johnson (NYSE:JNJGet Rating) by 0.5% in the 3rd quarter, Holdings Channel.com reports. The firm owned 14,345 shares of the company’s stock after buying an additional 75 shares during the period. Johnson & Johnson makes up approximately 2.2% of Summit Place Financial Advisors LLC’s investment portfolio, making the stock its 10th largest position. Summit Place Financial Advisors LLC’s holdings in Johnson & Johnson were worth $2,343,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in JNJ. Hemington Wealth Management lifted its position in shares of Johnson & Johnson by 1.1% during the 3rd quarter. Hemington Wealth Management now owns 18,604 shares of the company’s stock valued at $3,039,000 after acquiring an additional 196 shares during the last quarter. Keystone Wealth Services LLC boosted its position in shares of Johnson & Johnson by 1.3% in the 3rd quarter. Keystone Wealth Services LLC now owns 8,022 shares of the company’s stock valued at $1,310,000 after purchasing an additional 106 shares during the period. Fluent Financial LLC increased its stake in Johnson & Johnson by 3.8% in the 3rd quarter. Fluent Financial LLC now owns 40,407 shares of the company’s stock worth $6,601,000 after purchasing an additional 1,461 shares in the last quarter. Parthenon LLC boosted its holdings in shares of Johnson & Johnson by 0.4% in the third quarter. Parthenon LLC now owns 146,607 shares of the company’s stock worth $23,950,000 after buying an additional 610 shares during the period. Finally, Nepsis Inc. grew its position in Johnson & Johnson by 28.0% during the 3rd quarter. Nepsis Inc. now owns 86,542 shares of the company’s stock worth $14,138,000 after purchasing an additional 18,917 shares in the last quarter. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the transaction, the vice president now owns 40,133 shares in the company, valued at approximately $6,869,966.94. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares in the company, valued at $6,869,966.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider William Hait sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, October 24th. The shares were sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the completion of the sale, the insider now directly owns 80,236 shares of the company’s stock, valued at approximately $13,764,485.80. The disclosure for this sale can be found here. Insiders have sold 277,886 shares of company stock valued at $48,550,549 in the last three months. 0.35% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on JNJ shares. Citigroup raised their target price on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Bank of America lowered their target price on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research note on Friday, October 14th. SVB Leerink reduced their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday. Barclays started coverage on Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price target for the company. Finally, Sanford C. Bernstein lowered their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Stock Down 0.5 %

Shares of NYSE JNJ opened at $168.74 on Friday. The business has a fifty day moving average of $176.14 and a two-hundred day moving average of $171.25. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The stock has a market cap of $441.17 billion, a PE ratio of 23.50, a PEG ratio of 3.28 and a beta of 0.56.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.68%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.